EGFR and colorectal carcinoma: For example, RAS mutation status is not available in the database, so patients with an anti-EGFR antibody during the analysis period were presumed to have RAS-wild type CRC, and the potential for patients to change RAS mutation status during their treatment sequence was not considered.